Genprex

Monthly Archives: January 2022

Preclinical Data Show Potential for Use of Genprex’s ONCOPREX® Nanoparticle Delivery System in Treating Colon Cancer

Academic Research Lab Uses ONCOPREX Delivery System to Restore FAS Expression
in Mouse Metastatic Colon-Cancer Cells

Read More

Genprex’s REQORSA™ Immunogene Therapy: The First Systemic Gene Therapy Used for Cancer

Genprex, a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is a leader in gene therapy with a systemic gene therapy in development for non-small cell lung cancer (NSCLC).

Read More

Genprex to Accelerate Opening of Acclaim-1 Clinical Trial Sites for REQORSA™ Systemic Gene Therapy in Non-Small Cell Lung Cancer

Multiple clinical trial sites to be opened under oncology research network collaboration

Read More



Genprex to Participate in January Investor and Healthcare Conferences to Highlight Company’s Gene Therapies in Cancer and Diabetes

HC Wainwright BIOCONNECT 2022 Virtual Conference – January 10-13

Biotech Showcase 2022 – January 10-13

Precision: Lung Cancer World R&D Virtual Summit – January 25-26

CEO Roadshow – January 26

Read More


Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer

Pipeline Expansion Enables Company to Target Entire Lung Cancer Market with REQORSA™

Read More